Sumit Woods is a real estate developer specializing in residential and commercial redevelopment projects in Mumbai and Goa, earning revenue by rehabilitating existing society members and selling additional floor space to new buyers.
The company lacks a durable moat as evidenced by low average ROE (2.2%) and net margins (2.5%), indicating that its 'redevelopment specialist' branding does not translate into superior pricing power or cost advantages over competitors in the fragmented Mumbai market.
Management has prioritized project expansion and debt reduction through equity dilution, but historical returns on capital (ROCE 9.1%) are barely above the cost of debt, and EPS has declined at a -13.4% CAGR despite revenue growth.
The company's aggressive project expansion, funded by continuous equity dilution rather than internal cash flow, eventually hit a wall as the Mumbai real estate market cooled. With a cash conversion ratio of only 0.12, the reported profits remained trapped in illiquid inventory and receivables while interest obligations on debt consumed the remaining margins. The dilution from preferential warrants effectively transferred the remaining value from minority shareholders to insiders, and the lack of a competitive advantage meant the firm could not raise prices to offset rising construction costs, leading to a slow-motion collapse of book value.
RichFakir rates Sumit Woods Ltd's business quality as poor — 10/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Sumit Woods Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Sumit Woods Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Sumit Woods Ltd's fair value is about ₹9 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →